MedPath

Cabotegravir

Generic Name
Cabotegravir
Brand Names
Apretude, Vocabria
Drug Type
Small Molecule
Chemical Formula
C19H17F2N3O5
CAS Number
1051375-10-0
Unique Ingredient Identifier
HMH0132Z1Q
Background

Cabotegravir, or GSK1265744, is an HIV-1 integrase inhibitor that is prescribed with the non-nucleoside reverse transcriptase inhibitor, rilpivirine. Early research into cabotegravir showed it had lower oral bioavailability than dolutegravir, which resulted in the development of long acting monthly intramuscular injection formulation for cabotegravir.

Cabotegravir was granted FDA approval on 21 January 2021 in combination with rilpivirine to treat HIV-1 infection in virologically suppressed individuals. While previously administered once monthly only, this combination product was granted FDA approval for dosing every two months on February 01, 2022 and without the need for an oral lead-in period prior.

Indication

Oral cabotegravir is indicated in combination with rilpivirine for the short-term treatment of HIV-1 in virologically suppressed adults with no history of treatment failure to assess tolerability of cabotegravir or who have missed an injected dose of cabotegravir. Intramuscular extended-release cabotegravir in combination with rilpivirine is indicated as a complete regimen for the treatment of HIV-1 infection in adults and adolescents 12 years of age and older weighing at least 35 kg to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine.

An extended-release injectable suspension formulation of cabotegravir is also indicated for the prevention of sexually-acquired HIV-1 infection (i.e. for pre-exposure prophylaxis, PrEP) in at-risk adults and adolescents weighing at least 35kg.

Associated Conditions
Human Immunodeficiency Virus Type 1 (HIV-1), Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Associated Therapies
Oral Therapies
Clinical Trials
Related News

GSK's Linerixibat Shows Significant Improvement in Cholestatic Pruritus for Primary Biliary Cholangitis Patients

• GSK's phase III GLISTEN trial demonstrates linerixibat significantly improves cholestatic pruritus (relentless itch) in patients with primary biliary cholangitis, addressing a major quality of life concern. • The late-breaking results were presented at the European Association for the Study of the Liver (EASL) Congress 2025, highlighting the potential for a new treatment option for this challenging symptom. • Primary biliary cholangitis is a chronic autoimmune liver disease that primarily affects women, with pruritus being one of the most debilitating symptoms impacting daily functioning and quality of life.

ViiV Healthcare Showcases Long-Acting HIV Innovations and Pipeline Advances at CROI 2025

• Real-world data presented at CROI 2025 demonstrates zero HIV acquisitions and high persistence with Apretude (cabotegravir LA) for PrEP across diverse populations, reinforcing its effectiveness in HIV prevention. • Long-term follow-up data from multiple studies confirms the sustained efficacy and safety of Cabenuva (cabotegravir + rilpivirine LA) as a complete treatment regimen for people living with HIV. • Late-breaking phase IIb data reveals promising results for an investigational broadly neutralizing antibody (VH3810109) in combination with cabotegravir LA, potentially expanding long-acting treatment options.

Quebec Leads Canada in HIV Prevention: First to Cover Long-Acting Injectable PrEP APRETUDE

• Quebec becomes the first Canadian province to provide public reimbursement for APRETUDE, a long-acting injectable HIV prevention drug, through RAMQ coverage for at-risk individuals. • Real-world studies demonstrate over 99% effectiveness of APRETUDE for HIV prevention in nearly 1,300 individuals, showing superior efficacy compared to daily oral alternatives. • The decision comes as HIV cases in Quebec have surged 37% between 2019 and 2022, marking a significant step forward in addressing the rising infection rates.

GSK's Portfolio Resilience: Cancer and HIV Gains Offset RSV Vaccine Decline

• GSK experienced a significant 51% decline in Arexvy RSV vaccine sales to £590 million in 2024, following restricted US recommendations limiting use to adults 75 and older. • Strong performance in oncology with 72% sales growth to £408 million, driven by Jemperli and Ojjaara, while HIV portfolio showed double-digit growth through Cabenuva, Apretude, and Dovato. • Despite vaccine challenges, GSK upgraded its long-term sales forecast to £40 billion by 2031, supported by pipeline progress and planned launches in respiratory, oncology, and infectious diseases.

Global HIV/AIDS Crisis: Latest Statistics Show 40 Million Living with HIV as Prevention and Treatment Options Expand

• Recent global data reveals approximately 40 million people are currently living with HIV worldwide, with 1.2 million cases in the United States among individuals over 13 years old. • Advanced treatment options including integrase inhibitor-based regimens like Biktarvy have shown high efficacy, with PrEP medications demonstrating up to 99% effectiveness in preventing HIV transmission through sexual contact. • Pharmacists are gaining expanded roles in HIV care, with several states now allowing them to prescribe PrEP and PEP medications, improving accessibility to preventive treatments.

European Commission Approves Vocabria + Rekambys for HIV Treatment in Adolescents

• The European Commission has authorized Vocabria in combination with Rekambys for treating HIV-1 in adolescents aged 12 and older who are virologically suppressed. • This long-acting injectable regimen reduces the treatment burden from 365 daily pills to as few as six injections per year. • Clinical trials, including the MOCHA study, showed high rates of virologic suppression and a strong preference for the injectable regimen among adolescents. • The approval marks a significant step in providing more convenient and less stigmatizing treatment options for young people living with HIV.

FDA Grants Breakthrough Therapy Designation to GSK's Jemperli for Advanced Rectal Cancer

• The FDA granted Breakthrough Therapy Designation to GSK's Jemperli (dostarlimab) for locally advanced dMMR/MSI-H rectal cancer. • The designation was based on a Phase II trial showing a 100% clinical complete response rate in all 42 patients treated with dostarlimab. • Jemperli targets the PD-1 receptor and aims to improve the immune system's ability to eradicate cancer cells without traditional treatments. • The AZUR-1 trial is ongoing to confirm these findings, potentially changing the treatment paradigm for this subset of rectal cancer patients.

Twice-Yearly Lenacapavir Shot Shows Promise in HIV Prevention, Faces Access Challenges

• Lenacapavir, a twice-yearly injectable drug, has demonstrated near-perfect effectiveness in preventing HIV infections in clinical trials, marking a potential breakthrough in AIDS prevention. • Gilead, the drug's developer, plans to offer affordable generic versions in 120 low-income countries, primarily in Africa, Southeast Asia, and the Caribbean, but excludes most of Latin America. • Health experts and advocacy groups are raising concerns about equitable access, urging Gilead to expand the generic distribution deal to include Latin American nations where HIV infection rates are rising. • Experts suggest governments consider compulsory licensing to bypass patents and ensure affordable access to lenacapavir, especially for marginalized communities facing stigma and unequal healthcare access.

Lenacapavir: Twice-Yearly Injection Shows High Efficacy in HIV Prevention

• Lenacapavir, administered as a twice-yearly injection, demonstrates a 96% reduction in HIV infection risk compared to background incidence. • Clinical trials reveal lenacapavir's superior efficacy over daily oral PrEP medications like Truvada, particularly addressing adherence challenges. • The FDA is reviewing lenacapavir for potential approval in 2025, offering a promising long-acting option for HIV prevention. • Global health experts emphasize the importance of equitable access and affordability to ensure widespread adoption of lenacapavir.

FDA Accepts Gilead's Lenacapavir for HIV Prevention with Priority Review

• The FDA has accepted Gilead's NDA for lenacapavir, a twice-yearly injectable HIV-1 capsid inhibitor, as pre-exposure prophylaxis (PrEP). • Lenacapavir demonstrated 100% risk reduction in cisgender women and 96% risk reduction in a diverse population, compared to background HIV incidence. • The FDA has granted priority review with a target action date of June 19, 2025, potentially making it the first twice-yearly HIV prevention option. • Gilead is also pursuing global access, including submissions to the EMA and voluntary licensing agreements to facilitate availability in low- and middle-income countries.

GSK Announces Q3 2024 Results: Specialty Medicines Drive Growth, Pipeline Strengthens

• GSK's Q3 2024 sales reached £8.0 billion, with a 2% CER increase, driven by strong performance in Specialty Medicines, offsetting lower Vaccines sales. • R&D progress includes EU approval for Arexvy in adults aged 50-59 and positive Phase III results for depemokimab in chronic rhinosinusitis with nasal polyps (CRSwNP). • The company confirms its 2024 guidance, projecting a 7-9% turnover growth and a 10-12% increase in core EPS, excluding COVID-19 solutions. • A Q3 2024 dividend of 15p per share has been declared, with expectations to declare a 60p per share dividend for the full year.

Apretude Shows Over 99% Effectiveness in Real-World HIV Prevention Studies

• Real-world studies demonstrate Apretude (cabotegravir long-acting injectable) has over 99% effectiveness in preventing HIV, reinforcing its potential as a PrEP option. • The PILLAR implementation study reveals that Apretude reduces PrEP-related stigma and anxiety among men who have sex with men and transgender men, compared to daily oral PrEP. • Participants in the PILLAR trial reported high acceptability of Apretude, citing convenience and reduced worry about missing doses, despite some injection site reactions. • Flexible clinic scheduling, transportation assistance, and virtual appointments were identified as valuable facilitators of adherence to Apretude, enhancing its real-world impact.

ViiV Healthcare Triples HIV Prevention Drug Supply for Low-Income Nations

• ViiV Healthcare announces plans to provide 2 million doses of long-acting cabotegravir (Apretude) at not-for-profit pricing for low and middle-income countries through 2026. • The GSK-backed company has already initiated drug rollout in several nations including Zambia, Malawi, Zimbabwe, with plans to expand to nine additional countries by year-end. • This expansion of HIV prevention access aligns with ViiV's broader initiatives, including support for generic drug development through the Medicines Patent Pool agreement.

Gilead's Lenacapavir Shows Promise in HIV Prevention and Treatment

• Gilead's twice-yearly injectable lenacapavir reduced HIV infections by 96% in a Phase 3 trial, demonstrating superiority to daily oral Truvada for PrEP. • The PURPOSE 2 trial included cisgender men, transgender individuals, and gender non-binary people, showing broad efficacy across diverse populations. • Gilead plans to begin regulatory filings for lenacapavir for PrEP by the end of 2024, with potential launch in 2025, prioritizing access in high-incidence, resource-limited countries. • A Phase 2 trial of once-weekly oral islatravir and lenacapavir maintained viral suppression in adults with HIV, paving the way for Phase 3 trials.

Lenacapavir Shows High Efficacy in HIV Prevention, Faces Cost Accessibility Concerns

• Lenacapavir, a long-acting injectable HIV prevention drug, demonstrated 89% higher efficacy than daily oral medication in a key clinical trial. • Gilead Sciences' lenacapavir, dosed every six months, showed 100% efficacy in cisgender women, marking it as a potential game-changer. • Despite promising results, the high cost of lenacapavir raises concerns about equitable access and potential widening of racial disparities. • Gilead plans to seek FDA approval for lenacapavir as PrEP by year-end, with potential market availability by mid-to-late 2025.

Twice-Yearly Lenacapavir Injections Show 100% Efficacy in Preventing HIV in Women

• A clinical trial in South Africa and Uganda demonstrated that lenacapavir, administered via injection every six months, provided complete protection against HIV infection in young women. • The Purpose 1 trial compared lenacapavir to daily oral PrEP medications, Truvada (F/TDF) and Descovy (F/TAF), with lenacapavir showing significantly higher efficacy. • The trial's independent data safety monitoring board recommended halting the blinded phase due to the clear benefit of lenacapavir, offering all participants a choice of PrEP. • Gilead Sciences, the drug developer, plans to submit the trial results to regulatory bodies and the WHO, with hopes of incorporating lenacapavir into HIV prevention guidelines.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy